血脂领域的新进展  

Update on the management of dyslipidemia

作　　者：耿慧[1] 刘梅林[1] 

机构地区：[1]北京大学第一医院老年内科,北京100034

出　　处：《临床心血管病杂志》2014年第2期95-98,共4页Journal of Clinical Cardiology

基　　金：国家科技支撑计划项目(No:2012BAI37B05)

摘　　要：血脂异常是心脑血管疾病重要的危险因素。近年来,血脂领域相关研究促进了心血管病防治理念的更新。新的研究表明,PCSK9单克隆抗体未来有可能成为血脂,尤其是家族性高胆固醇血症治疗的新突破;烟酸类药物联合他汀类药物缺乏更多心血管保护作用;他汀类药物的安全性以及在特殊人群中的应用引起更多关注。本文对血脂领域的国际大规模临床试验结果及相关进展进行回顾。Dyslipidemia is an important risk factor for cardiovascular and cerebrovascular disease.New researches on management of dyslipidemia promote updates in prevention and treatment of cardiovascular disease.Recent studies show that pharmacologic inhibition of PCSK9might be a promising therapeutic area in lowering LDL cholesterol levels,especially in patients with familial hypercholesterolemia.Extended-release niacin with laropiprant offered no benefits beyond statin therapy alone in reducing the risk of major vascular events.Safety and application in specific population of statin therapy have been addressed to more attention.This review focus on recent clinical trials and management of dyslipidemia.

关 键 词：调脂治疗 PCSK9 烟酸 他汀 安全性 临床试验 

分 类 号：R589.2[医药卫生—内分泌]